David Rintell, Ed.D.
Dr. Rintell is head of patient advocacy for Aspa Therapeutics and parent company BridgeBio Pharma and QED Therapeutics. He is dedicated to strengthening Aspa Therapeutics’ ties with patient advocacy organizations and implementing BridgeBio’s core value of Putting Patients First. Previously, Dr. Rintell headed global patient advocacy for rare diseases at Sanofi Genzyme in Cambridge, Massachusetts. There, he led an international team working with patient organizations in lysosomal storage disorders, genetic ocular diseases and ATTR amyloidosis. Prior to joining the biotech industry, Dr. Rintell held clinical appointments at two Harvard Medical School-affiliated hospitals, Massachusetts General Hospital and the Brigham and Women’s Hospital. As a clinical psychologist, he assessed and treated patients with chronic diseases, with a specialization in helping children and adults with multiple sclerosis. He also served on the faculty of Brandeis University’s graduate program in genetic counselling, where he trained future professionals who will help families understand genetic conditions. He served several patient advocacy organizations as a board member, member of clinical advisory committees and volunteer. His many publications focus on the psychosocial impact of medical illness and psychosocial adaptation to chronic medical illness. He is a clinical instructor in psychiatry at Harvard Medical School, and Professor of the Practice Emeritus at Brandeis University. Dr. Rintell holds a Doctor of Education in Counseling Psychology from Boston University.